Indegene’s business model is easiest to understand if you think of what happens after a pharma company discovers a drug.

Big pharma companies like Pfizer or Novartis spend billions on R&D to discover and test drugs.

But once a drug is approved, a new and equally complex challenge begins — how to take that drug to market globally, communicate with doctors, manage regulatory requirements, and continuously monitor safety.

This "post-discovery" work is massive, repetitive, highly regulated, and requires deep domain expertise.

Indegene sits right in the middle of this layer.

Instead of pharma companies building large internal teams to handle everything from medical writing to marketing campaigns to compliance documentation, they outsource this entire operational layer to Indegene.

Think of it as an "execution partner" for pharma commercialization and medical operations.

Indegene doesn’t discover drugs — it helps bring them to market efficiently, at scale, and in a compliant way.

The business is broadly split into two engines.

First is the Commercial side (roughly ~70% of revenue). This is focused on how drugs are marketed and promoted globally.

Indegene helps pharma companies create and adapt marketing content for doctors, run omnichannel digital campaigns, personalize engagement with healthcare professionals, and manage data-driven marketing operations across different geographies. In simple terms, it runs the "marketing execution engine' for pharma companies.

Think of Indegene’s EMS as an operations outsourcing partner for pharma companies — the layer that helps a drug reach doctors, get understood, and get prescribed.

Like banks outsourcing IT support or retailers outsourcing logistics, pharma companies outsource medical and commercial operations to Indegene. It delivers these workflows faster, cheaper, and with better technology than most in-house setups.

Second is the Medical and Regulatory side (roughly ~25% of revenue). This is the high-compliance, science-heavy layer.

It includes medical writing for clinical studies, drug safety reporting (pharmacovigilance), regulatory submissions to agencies like the FDA and EMA, and support for medical affairs teams. This is mission-critical work where accuracy and compliance are non-negotiable.

The remaining portion comes from smaller technology, consulting, and staffing-related services.

What makes Indegene’s model interesting is not just what it does, but how it gets paid.

A large part of its revenue comes from output-based pricing — meaning clients pay per document, per campaign output, or per deliverable.

This aligns incentives around efficiency. On top of that, Indegene also signs multi-year contracts (typically 3–5 years), which provides stable, recurring revenue visibility. A smaller portion comes from time-and-material projects.

The bigger picture is structural. Pharma companies are under constant pressure to reduce costs due to pricing regulations, while also needing to scale global drug launches faster and more efficiently.

At the same time, the complexity of regulatory and marketing environments is increasing, and AI adoption is pushing companies to partner with specialized firms rather than build everything in-house.

Indegene benefits from all of these trends by positioning itself as a specialized, AI-enabled execution layer for the pharma industry.

In short, Indegene doesn’t compete with pharma companies — it powers a large part of their post-drug-discovery operations, sitting quietly in one of the most critical and underappreciated parts of the healthcare value chain.read